Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ADCT 
ADC Therapeutics SA (ADCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: ADCT (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8
1 Year Target Price $8
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 431.32% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 437.29M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 6 | Beta 1.89 | 52 Weeks Range 1.05 - 4.80 | Updated Date 12/25/2025 |
52 Weeks Range 1.05 - 4.80 | Updated Date 12/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -221.97% | Operating Margin (TTM) -186.23% |
Management Effectiveness
Return on Assets (TTM) -23.98% | Return on Equity (TTM) -705.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 319814201 | Price to Sales(TTM) 5.81 |
Enterprise Value 319814201 | Price to Sales(TTM) 5.81 | ||
Enterprise Value to Revenue 4.25 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 123877111 | Shares Floating 107806533 |
Shares Outstanding 123877111 | Shares Floating 107806533 | ||
Percent Insiders 13.76 | Percent Institutions 58.6 |
Upturn AI SWOT
ADC Therapeutics SA
Company Overview
History and Background
ADC Therapeutics SA was founded in 2011 with the aim of developing highly potent antibody-drug conjugates (ADCs) for the treatment of cancer. Key milestones include the initiation of clinical trials for its lead candidates and subsequent regulatory filings. The company has evolved to focus on a pipeline of novel ADCs targeting specific hematological malignancies and solid tumors.
Core Business Areas
- Oncology Drug Development: ADC Therapeutics SA is primarily focused on the research, development, and commercialization of novel antibody-drug conjugates (ADCs) for the treatment of cancer. Their core business is driven by their proprietary ADC technology platform and a pipeline of investigational therapies.
Leadership and Structure
ADC Therapeutics SA is led by a management team with extensive experience in the biotechnology and pharmaceutical industries. The organizational structure is typical for a clinical-stage biopharmaceutical company, with dedicated departments for research and development, clinical operations, regulatory affairs, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Zynlonta (loncastuximab tesirine-lpyl): Zynlonta is a CD19-targeted ADC indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Its competitors include other CD19-targeted therapies and other agents used in the treatment of relapsed/refractory DLBCL. Market share data for this specific product in the broader relapsed/refractory DLBCL market is not readily available as it is a niche indication, but it competes with other established therapies.
Market Dynamics
Industry Overview
The oncology drug development industry, particularly the antibody-drug conjugate (ADC) sector, is experiencing rapid growth driven by advancements in targeting technologies, improved drug delivery systems, and a high unmet medical need for effective cancer treatments. The market is characterized by intense research and development, strategic partnerships, and significant investment.
Positioning
ADC Therapeutics SA is positioned as an emerging player in the ADC space, focusing on developing innovative ADCs for hematological malignancies and solid tumors. Its competitive advantages lie in its proprietary ADC technology and its pipeline of targeted therapies with potential for improved efficacy and safety profiles.
Total Addressable Market (TAM)
The total addressable market for oncology drugs, including ADCs, is vast and growing, driven by increasing cancer incidence globally. For specific indications like relapsed/refractory DLBCL, the TAM is in the billions of dollars. ADC Therapeutics SA is positioned to capture a portion of this market with its approved and pipeline assets.
Upturn SWOT Analysis
Strengths
- Proprietary ADC technology platform
- Clinical-stage pipeline with promising candidates
- Experienced management team
- Approved product (Zynlonta) in the market
Weaknesses
- Reliance on a limited number of lead candidates
- Need for significant capital for R&D and commercialization
- Potential for manufacturing challenges with complex biologics
- Limited commercial track record compared to larger pharmaceutical companies
Opportunities
- Expansion of Zynlonta into other indications or earlier lines of therapy
- Advancement of pipeline candidates through clinical trials
- Strategic partnerships and collaborations
- Growing adoption of ADCs in oncology treatment
Threats
- Clinical trial failures or delays
- Regulatory hurdles and approvals
- Intense competition from other pharmaceutical and biotechnology companies
- Pricing pressures and reimbursement challenges
- Emergence of new therapeutic modalities
Competitors and Market Share
Key Competitors
- Seagen Inc. (SGEN)
- Gilead Sciences, Inc. (GILD)
- AbbVie Inc. (ABBV)
- ImmunoGen, Inc. (IMGN)
Competitive Landscape
ADC Therapeutics SA faces strong competition from established pharmaceutical companies and specialized biotechnology firms with robust ADC pipelines and commercial infrastructure. Its advantages lie in its focused approach to ADC development and its proprietary technology, while disadvantages may include its smaller size and less diversified portfolio compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: ADC Therapeutics SA has demonstrated growth through the advancement of its pipeline, securing regulatory approval for Zynlonta, and expanding its research capabilities. Its growth trajectory is intrinsically linked to its success in developing and commercializing novel ADC therapies.
Future Projections: Future growth projections for ADC Therapeutics SA are contingent on the successful development and commercialization of its pipeline assets, including potential label expansions for Zynlonta and the progression of other investigational ADCs through clinical trials. Analyst estimates would provide specific growth outlooks.
Recent Initiatives: Recent initiatives likely include ongoing clinical trials for pipeline candidates, strategic partnerships, manufacturing expansions, and efforts to drive commercial success for Zynlonta.
Summary
ADC Therapeutics SA is a promising biotechnology company focused on developing novel antibody-drug conjugates for cancer treatment. Its strength lies in its proprietary technology and approved product, Zynlonta. However, it faces significant competition and requires substantial capital for continued research and development. Continued success hinges on pipeline advancement and effective commercialization strategies, while navigating regulatory and market challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings (e.g., 10-K, 10-Q)
- Financial news and analysis websites
- Industry research reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial or investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADC Therapeutics SA
Exchange NYSE | Headquaters - | ||
IPO Launch date 1979-03-16 | CEO & Director Dr. Ameet Mallik M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 263 | Website https://www.adctherapeutics.com |
Full time employees 263 | Website https://www.adctherapeutics.com | ||
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.